Browsing by Author Oliveira, Mafalda
Showing results 5 to 9 of 9
< previous
| Issue Date | Title | Author(s) |
|---|---|---|
| 19-Mar-2021 | Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer | Griguolo, Gaia; Serna, G.; Pascual, Tomás; Fasani, R.; Guardia, X.; Chic Ruché, Núria; Paré, Laia; Pernas, Sònia; Muñoz Mateu, Montserrat; Oliveira, Mafalda; Vidal, M.; Llombart Cussac, Antonio; Cortés, Javier; Galván, Patricia; Bermejo de las Heras, Begoña; Martínez, N.; López, R.; Morales, Serafín; Garau, Isabel; Manso, Luis; Alarcón, Jesús; Martínez, E.; Villagrasa, Patricia; Prat Aparicio, Aleix; Nuciforo, Paolo |
| 11-Jul-2024 | Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response | Brasó-maristany, Fara; Ferrero-cafiero, Juan Manuel; Falato, Claudette; Martínez Sáez, Olga; Cejalvo, Juan Miguel; Margelí Vila, Mireia; Tolosa, Pablo; Salvador-bofill, Francisco Javier; Cruz, Josefina; González-farré, Blanca; Sanfeliu, Esther; Òdena, Andreu; Serra, Violeta; Pardo, Francisco; Luna Barrera, Ana María; Arumi, Miriam; Guerra, Juan Antonio; Villacampa, Guillermo; Sánchez Bayona, Rodrigo; Ciruelos, Eva; Espinosa-bravo, Martín; Izarzugaza, Yann; Galván, Patricia; Matito, Judit; Pernas, Sonia; Vidal, Maria; Santhanagopal, Anu; Sellami, Dalila; Esker, Stephen; Fan, Pang-dian; Suto, Fumitaka; Vivancos, Ana; Pascual, Tomás; Prat, Aleix; Oliveira, Mafalda |
| 20-Jan-2020 | Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade | Brasó Maristany, Fara; Griguolo, Gaia; Pascual, Tomás; Paré, Laia; Nuciforo, Paolo; Llombart Cussac, Antonio; Bermejo de las Heras, Begoña; Oliveira, Mafalda; Morales, Serafín; Martínez, Noelia; Vidal Losada, Maria Jesús; Adamo, Barbara; Martínez, Olga; Pernas, Sònia; López, Rafael; Muñoz Mateu, Montserrat; Chic Ruché, Núria; Galván, Patricia; Garau, Isabel; Manso, Luis; Alarcón, Jesús; Martínez, Eduardo; Gregorio, Sara; Gomis, Roger R.; Villagrasa, Patricia; Cortés, Javier; Ciruelos, Eva; Prat Aparicio, Aleix |
| 9-Jan-2019 | Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial | Gavilá, Joaquín; Oliveira, Mafalda; Pascual, Tomás; Perez-Garcia, Jose; Gonzàlez, Xavier; Canes, Jordi; Paré, Laia; Calvo Serrano, Isabel; Ciruelos, Eva; Muñoz Mateu, Montserrat; Virizuela, Juan A.; Ruiz, Isabel; Andrés, Raquel; Perelló, Antonia; Martínez, Jerónimo; Morales, Serafín; Marín Aguilera, Mercedes; Martínez, Debora; Quero, Juan C.; Llombart-Cussac, Antonio; Prat Aparicio, Aleix |
| 23-Apr-2021 | SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer | Pascual, Tomás; Oliveira, Mafalda; Ciruelos, Eva; Bellet Ezquerra, Meritxell; Saura, Cristina; Gavilá, Joaquin; Pernas, Sònia; Muñoz Mateu, Montserrat; Vidal Losada, Maria Jesús; Margelí Vila, Mireia; Cejalvo Andújar, Juan Miguel; González Farré, Blanca; Espinosa Bravo, Martin; Cruz, Josefina; Salvador Bofill, Francisco Javier; Guerra, Juan Antonio; Luna Barrera, Ana María; Arumi de Dios, Miriam; Esker, Stephen; Fan, Pang-dian; Martínez Sáez, Olga; Villacampa, Guillermo; Paré, Laia; Ferrero Cafiero, Juan M.; Villagrasa, Patricia; Prat Aparicio, Aleix |